PREMIER BIOMEDICAL INC
BIEI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BIEI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$1.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2019.
Tracking 1 clinical trial for PREMIER BIOMEDICAL INC.
Run PREMIER BIOMEDICAL INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PREMIER BIOMEDICAL INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Financials
Frequently asked questions
Who is the CEO of PREMIER BIOMEDICAL INC?
William Hartman is the chief executive officer of PREMIER BIOMEDICAL INC (BIEI).
Where is PREMIER BIOMEDICAL INC headquartered?
PREMIER BIOMEDICAL INC (BIEI) is headquartered in Jackson Center, PA, United States.
What therapeutic areas does PREMIER BIOMEDICAL INC focus on?
PREMIER BIOMEDICAL INC develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Infectious Disease, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.